Histologic findings of liver injury during pembrolizumab-axitinib treatment.

Abstract

Hepatotoxicity is a significant concern in systemic cancer treatments. The pembrolizumab-axitinib combination, used in advanced renal cell carcinoma (RCC), is associated with a 22% incidence of ≥G3 liver enzyme elevations. In this case report we provide the first description of liver biopsy findings of axitinib or pembrolizumab-axitinib drug-induced liver injury (DILI). These findings may enhance understanding of the hepatotoxic effects of this combination and inform strategies for patient management.